Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 3
2009 2
2010 3
2011 2
2012 7
2013 2
2014 20
2015 1
2016 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25394078

41 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice.
Costarelli S, Cozzi-Lepri A, Lapadula G, Bonora S, Madeddu G, Maggiolo F, Antinori A, Galli M, Di Perri G, Viale P, d'Arminio Monforte A, Gori A; ICONA Foundation Study Group. Costarelli S, et al. PLoS One. 2016 Oct 7;11(10):e0160761. doi: 10.1371/journal.pone.0160761. eCollection 2016. PLoS One. 2016. PMID: 27716843 Free PMC article.
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort.
Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Antinori A, Monforte AD; ICONA Foundation Study. Di Biagio A, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19825. doi: 10.7448/IAS.17.4.19825. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397569 Free PMC article.
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, Lorenzini P, Fabbiani M, Tommasi C, Latini A, Ammassari A, Loiacono L, Sterrantino G, Bellagamba R, Boumis E, Antinori A, Zaccarelli M. Pinnetti C, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19812. doi: 10.7448/IAS.17.4.19812. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397556 Free PMC article.
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group. Bunupuradah T, et al. Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Antivir Ther. 2012. PMID: 23075703 Clinical Trial.
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy.
Cozzi-Lepri A, Antinori A, Bonora S, Cingolani A, Cassola G, Angarano G, Vullo V, Mussini C, Gori A, Maggiolo F, Castagna A; d’Arminio Monforte on behalf of the ICONA Foundation Study, Antonella. Cozzi-Lepri A, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19771. doi: 10.7448/IAS.17.4.19771. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397515 Free PMC article.
41 results